Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma

…, N Devoogdt, H Everaert, C Ackaert… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor characteristics
in breast cancer to guide therapy. Anti-HER2 treatment has clear survival advantages …

[HTML][HTML] Immunogenicity risk profile of nanobodies

C Ackaert, N Smiejkowska, C Xavier… - Frontiers in …, 2021 - frontiersin.org
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a
promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess …

[HTML][HTML] The impact of nitration on the structure and immunogenicity of the major birch pollen allergen Bet v 1.0101

C Ackaert, S Kofler, J Horejs-Hoeck, N Zulehner… - PloS one, 2014 - journals.plos.org
Allergy prevalence has increased in industrialized countries. One contributing factor could be
pollution, which can cause nitration of allergens exogenously (in the air) or endogenously (…

Nitration of the birch pollen allergen Bet v 1.0101: efficiency and site-selectivity of liquid and gaseous nitrating agents

K Reinmuth-Selzle, C Ackaert, CJ Kampf… - Journal of proteome …, 2014 - ACS Publications
Nitration of the major birch pollen allergen Bet v 1 alters the immune responses toward this
protein, but the underlying chemical mechanisms are not yet understood. Here we address …

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays

A Ducret, C Ackaert, J Bessa, C Bunce, T Hickling… - MAbs, 2022 - Taylor & Francis
A major impediment to successful use of therapeutic protein drugs is their ability to induce
anti-drug antibodies (ADA) that can alter treatment efficacy and safety in a significant number …

Identification of useful nanobodies by phage display of immune single domain libraries derived from camelid heavy chain antibodies

…, N Devoogdt, C Ackaert… - Current …, 2016 - ingentaconnect.com
Background: The discovery of functional heavy chain-only antibodies devoid of light chains
in sera of camelids and sharks in the early nineties provided access to the generation of …

[HTML][HTML] Stabilization of the dimeric birch pollen allergen Bet v 1 impacts its immunological properties

S Kofler, C Ackaert, M Samonig, C Asam, P Briza… - Journal of Biological …, 2014 - ASBMB
Many allergens share several biophysical characteristics, including the capability to undergo
oligomerization. The dimerization mechanism in Bet v 1 and its allergenic properties are so …

Determination of nitration degrees for the birch pollen allergen Bet v 1

K Selzle, C Ackaert, CJ Kampf, AT Kunert… - Analytical and …, 2013 - Springer
Nitration of tyrosine residues in the major birch pollen allergen Bet v 1 may alter the allergenic
potential of the protein. The kinetics and mechanism of the nitration reaction, however, …

[HTML][HTML] Immunopeptidomic data integration to artificial neural networks enhances protein-drug immunogenicity prediction

C Barra, C Ackaert, B Reynisson, J Schockaert… - Frontiers in …, 2020 - frontiersin.org
Recombinant DNA technology has, in the last decades, contributed to a vast expansion of
the use of protein drugs as pharmaceutical agents. However, such biological drugs can lead …

Enzyme therapy in Fabry disease: severe adverse events associated with anti‐agalsidase cross‐reactive IgG antibodies

…, A Reberga, M Thetis, C Ackaert… - British journal of …, 2009 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Fabry disease is an X‐linked lysosomal
storage disorder related to α‐galactosidase A deficiency. • Two enzyme replacement …